| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A cryptic translocation leading to NUP98-PHF23 fusion in AML
|
Ning, Yi
|
|
2016
|
29 |
4 |
p. 320-323
4 p.
|
artikel
|
| 2 |
AML in 2016: Where we are now?
|
Rowe, Jacob M.
|
|
2016
|
29 |
4 |
p. 315-319
5 p.
|
artikel
|
| 3 |
Chimeric antigen receptor T cell therapy in AML: How close are we?
|
Gill, Saar
|
|
2016
|
29 |
4 |
p. 329-333
5 p.
|
artikel
|
| 4 |
Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission
|
Appelbaum, Frederick R.
|
|
2016
|
29 |
4 |
p. 365-371
7 p.
|
artikel
|
| 5 |
Editorial Board / Aims & Scope
|
|
|
2016
|
29 |
4 |
p. iii-
1 p.
|
artikel
|
| 6 |
How important is NK alloreactivity and KIR in allogeneic transplantation?
|
Shaffer, Brian C.
|
|
2016
|
29 |
4 |
p. 351-358
8 p.
|
artikel
|
| 7 |
Index
|
|
|
2016
|
29 |
4 |
p. I-
1 p.
|
artikel
|
| 8 |
Innate immunity and the new forward genetics
|
Beutler, Bruce
|
|
2016
|
29 |
4 |
p. 379-387
9 p.
|
artikel
|
| 9 |
Is there justification for 4 cycles of consolidation therapy in AML?
|
Schlenk, Richard F.
|
|
2016
|
29 |
4 |
p. 341-344
4 p.
|
artikel
|
| 10 |
Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?
|
Litzow, Mark R.
|
|
2016
|
29 |
4 |
p. 345-350
6 p.
|
artikel
|
| 11 |
The role of second transplants for leukemia
|
Weisdorf, Daniel
|
|
2016
|
29 |
4 |
p. 359-364
6 p.
|
artikel
|
| 12 |
What is the role of novel thrombopoietic agents in the management of acute leukemia?
|
Kuter, David J.
|
|
2016
|
29 |
4 |
p. 372-378
7 p.
|
artikel
|
| 13 |
Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?
|
Estey, Elihu
|
|
2016
|
29 |
4 |
p. 324-328
5 p.
|
artikel
|
| 14 |
Why the stagnation in effective therapy for MDS?
|
Blum, William
|
|
2016
|
29 |
4 |
p. 334-340
7 p.
|
artikel
|
Tijdschrift beschrijving